Demant (DEMANT.CO) Stock Analysis & AI Equity Report
Demant (DEMANT.CO) overview
Demant (DEMANT.CO) stock analysis and AI equity research. For the latest completed financial year, 2024, Demant reported revenue of DKK 22,419m and operating profit of DKK 4,404m; the year-end share price was N/A and market capitalisation was N/A. Demant is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Demant's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-06-14. Data will be refreshed during report generation.
About Demant
Demant A/S is a Denmark-based hearing healthcare group that develops, manufactures and sells hearing aids, hearing care services and diagnostic equipment. Its operations span retail hearing care clinics, branded hearing aid solutions and hearing and balance assessment instruments used by audiologists, ENT specialists and balance clinics in global markets.
Generate the Demant report
Demant is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Demant and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.